A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors
Yasuki Hijikata(Kyushu University Hospital), Kenzaburo Tani(Tokyo Medical University), Yuichi Yamada(Kyushu University), Kazunari Yamada(Kyushu University Hospital), Mutsunori Murahashi(Kyushu University Hospital), Yoshihiro Tanaka(Kyushu University Hospital), Yoshinao Oda(Kyushu University), Hiroyuki Inoue(Fukuoka University), Atsushi Takahashi(Fukushima Medical University), Yusuke Nakamura(Rissho University), Yoichi Nakanishi(RIKEN Center for Integrative Medical Sciences), Toshihiko Okazaki(Johns Hopkins University), Junji Kishimoto(Kyushu University Hospital)
Cited by 17
Related Papers
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1
|Nature Genetics|2000|950
An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy
|Nature|1998|804
SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations
|Nature Genetics|2008|728
Comparative genetic architectures of schizophrenia in East Asian and European populations
|Nature Genetics|2019|709